This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Newest Treatments for Hepatitis C: Draft Report
This draft report was prepared by ICER for consideration of the CTAF Panel during a public meeting. This assessment addresses the following questions: 1) among patients with genotype 1, what is the comparative clinical effectiveness of combinations of two or more DAAs compared to each other as well as to single DAA therapy used in combination with interferon and ribavirin; and 2) what is the comparative value of the new therapies, including analysis of their care value at the patient level and of their potential health system value when budget impact is also taken into consideration.View All Materials on this Topic or Go Back to View More Materials